BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioMarin Pharmaceutical Inc (BMRN) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has potential growth drivers, the recent financial performance, lack of strong trading signals, and mixed analyst sentiment suggest a cautious approach. Holding the stock or waiting for more favorable entry points is recommended.
The technical indicators show a neutral to slightly bearish trend. The MACD histogram is negative (-0.417) and contracting, RSI is at 42.054 (neutral zone), and moving averages are converging. The stock is trading below the pivot level of 56.575, with key support at 53.765 and resistance at 59.384. This indicates no clear upward momentum.
The company has strong societal attention due to its focus on rare diseases, as evidenced by the success of CNBC Cures initiatives. Analyst updates highlight potential growth drivers like the Voxzogo indication expansion and the Amicus acquisition, which could add value in the long term.
The company faces competitive headwinds for its Voxzogo franchise, with upcoming challenges from rival drugs. Financial performance in Q4 2025 showed a significant decline in net income (-137.28% YoY) and EPS (-137.50% YoY), despite revenue growth. Analysts have lowered price targets recently, reflecting cautious sentiment.
In Q4 2025, revenue increased by 17.03% YoY to $874.57M, showing strong top-line growth. However, net income dropped significantly to -$46.57M (-137.28% YoY), and EPS fell to -0.24 (-137.50% YoY). Gross margin improved slightly to 81.55%, up 1.32% YoY, but overall profitability remains a concern.
Analyst sentiment is mixed. Several analysts maintain Buy or Overweight ratings, with price targets ranging from $55 to $105. However, some firms have lowered their targets recently, citing competitive pressures and cautious assumptions. The average sentiment reflects cautious optimism but lacks strong conviction.
